Chapter 15 - The Gathering of the Cohort
By mid-week, the news from Bethesda had rippled through the global oncological community like a seismic shockwave.
What had begun as a quiet clinical trial conducted under the umbrella of a private family foundation in the Virginia hills had suddenly become the focal point of modern oncology. The front gate of the Sterling Estate was no longer approached by corporate raiders in limousines; it was surrounded by medical transport vans, satellite broadcast trucks, and delegations of pediatric specialists arriving from Boston, Houston, and London.
At 9:00 AM on a crisp Thursday morning, the great ballroom—once the setting for my sister's calculated social maneuvers—was filled with forty clinical desks, each equipped with dedicated telemetry feeds linked directly to our partner imaging centers across the mid-Atlantic.
Julian Vance stood at the center podium on the elevated dais, a wireless earpiece humming with updates from the regional coordinating centers. Behind him, on the fifty-foot projection array that had replaced the estate’s gilded mirrors, live clinical data streams updated in real time:
ACTIVE TRIAL COHORT: 84 PATIENTS.
PARTIAL RESPONSE: 91.2%.
COMPLETE MOLECULAR REMISSION: 76.8%.
GRADE 4 ADVERSE EVENTS: 0.
"We have twelve more admissions arriving from the Children's Hospital of Philadelphia at noon," Julian announced into the microphone, his voice crisp, authoritative, and entirely unbothered by the three dozen reporters seated in the gallery behind the velvet ropes. "All pediatric patients will be accommodated in the north residential pavilions. Zero out-of-pocket costs for families. Travel, lodging, and ongoing home health monitoring are fully covered under Section Four of the foundation’s endowment."
A reporter from the Washington Post raised her hand from the second row. "Mr. Vance, pharmaceutical representatives from Basel and New Jersey have stated publicly this morning that your protocol is operating outside standard FDA commercialization pipelines. They are questioning the sustainability of providing a multi-million-dollar molecular biologic free of charge. How long can the Sterling-Blackwood Foundation maintain this burn rate without private equity capitalization?"
Before Julian could answer, the side doors of the dais clicked open.
I walked onto the stage.
I wore a dark charcoal trouser suit cut with razor-sharp precision, a cream silk blouse, and my mother’s simple silver watch on my left wrist. My dark hair was swept up into an elegant, unpretentious chignon, and on my face was the serene, immovable poise of a woman who had already won the only battle that mattered.
Beside me walked Ethan, dressed in his white clinical lab coat over his suit, carrying a thick binder of verified pharmacokinetic logs.
The room fell into an immediate, respectful hush. The chatter of the journalists died down, replaced by the synchronized, rapid clicking of sixty camera shutters.
"I can answer that question, Ms. Davis," I said, stepping up to the secondary microphone.
My voice was not loud, but it possessed that quiet, crystalline clarity that commanded absolute stillness.
"The pharmaceutical representatives you speak of," I continued, resting my hands lightly on the podium, "are calculating sustainability based on a model of infinite shareholder extraction. They believe that a medicine is only sustainable if it generates a ninety-percent profit margin for venture capital holding firms."
I turned slightly, gesturing toward the data array displaying the clinical response metrics behind me.
"Our foundation was not capitalized by Wall Street. It was capitalized by the restitution of stolen family trusts, the recovered assets of corporate criminals, and an irrevocable admiralty salvage covenant that has stood for over half a century. We do not have shareholders. We have patients. And as long as the artesian wells of this estate continue to flow, our burn rate is not determined by the price of our stock, but by the number of children who need to go home to their parents."
The reporter started to ask a follow-up, but I raised one hand, cutting off the interruption with effortless authority.
"Furthermore," I added, looking directly into the primary lens of the national network camera in the center aisle, "to any corporate entity considering an intellectual property challenge or an administrative blockade against our distribution pipelines: our legal defense fund is chaired by Arthur Vance, our sovereign charter is ratified by the Department of the Interior, and our ledgers are audited by the federal judiciary."
I offered a small, cool smile that held all the majesty of an unassailable fortress.
"We welcome the fight. But I suggest you check the balance sheets of the last three groups who tried to take this family down before you spend your legal retainers."
The ballroom erupted into a spontaneous, thunderous ovation from the clinical staff, researchers, and patient advocates lining the walls.
Ethan stepped up beside me, his arm sliding naturally around my waist, his warm hand resting securely against my hip. He leaned down, his lips brushing my ear as the applause echoed off the plaster reliefs of the high ceiling.
May you like
"A formidable performance, Madam Chairwoman," Ethan whispered, his voice rich with quiet amusement and boundless pride.
"A necessary one, Dr. Hart," I murmured back, smiling as I looked down at the room full of healers. "Now... let's go meet the children from Philadelphia."
